BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10640214)

  • 1. The histopathology of chronic myeloproliferative diseases.
    Georgii A; Buesche G; Kreft A
    Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
    Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
    Bartl R; Frisch B; Wilmanns W
    Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
    Nafe R; Holgado de Colombo S; Choritz H; Georgii A
    Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic myeloproliferative disorders. The new WHO classification].
    Thiele J; Kvasnicka HM
    Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
    Campr V
    Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy].
    Matolcsy A; Kónya T; Wéber E
    Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.
    Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
    J Clin Pathol; 1986 Mar; 39(3):237-52. PubMed ID: 3457024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J; Kvasnicka HM; Vardiman J
    Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.